– USA, FL – KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced the appointment of Tamara Seymour to its Board of Directors as Chair of the Audit Committee.
Ms. Seymour brings to KemPharm more than 30 years of life sciences industry experience, including 20 years in the role of CFO. She currently serves as a board member and audit committee chair of Artelo Biosciences, Inc. and Kintara Therapeutics, Inc., both publicly-traded clinical-stage biopharmaceutical companies.
“The addition of Tamara to our Board of Directors and her appointment as Chair of the Audit Committee comes at an important phase in the evolution of KemPharm and continues what has been a transformative period for the company,” said Chairman, President and CEO, Dr. Travis Mickle.
He added: “Tamara possesses an unrivaled combination of financial and life sciences industry experience, which will bring a new perspective and a depth of business acumen that will benefit our shareholders as we seek to leverage our strong financial position to target organic and external growth opportunities that, we believe, will ultimately build shareholder value. On behalf of the Board, I am pleased to welcome Tamara to KemPharm and look forward to benefitting from her knowledge and expertise.”
About Tamara Seymour
Tamara Seymour has served as CFO for several companies, including Signal Genetics, Inc., a publicly-traded molecular diagnostics company, HemaQuest Pharmaceuticals, Inc., a venture-backed clinical-stage drug development company and Favrille, Inc., a publicly-traded clinical-stage drug development company, and Interim CFO for Immunic, Inc., a publicly-traded clinical-stage drug development company. Her extensive experience includes leading multiple private and public financings, M&A transactions, the initial public offering for Favrile, as well as leading finance, investor relations, human resources, administration, and managed care payor reimbursement functions.
Ms. Seymour also served in public accounting for eight years, primarily with Deloitte & Touche LLP and PricewaterhouseCoopers LLP. Ms. Seymour is a Certified Public Accountant. She earned an MBA, emphasis in Finance, from Georgia State University, and a BBA, emphasis in Accounting, from Valdosta State University.
“It is an honor to join the KemPharm Board at this exciting and transformational juncture for the Company. I look forward to working with the Board and management to build upon the work that has been done to create long-term value for all stakeholders,” said Ms. Seymour.
About KemPharm
KemPharm is a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its proprietary LAT technology. KemPharm utilizes its proprietary LAT technology to generate improved prodrug versions of FDA-approved drugs as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. KemPharm’s prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, or ADHD, stimulant use disorder, and CNS rare diseases, including idiopathic hypersomnia. KemPharm’s lead clinical development candidate for the treatment of SUD, KP879, is based on its prodrug of d-methylphenidate, known as dexmethylphenidate. In addition, KemPharm has received FDA approval for AZSTARYSTM, a new once-daily treatment for ADHD in patients age six years and older, and APADAZ, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen.
For more information: https://kempharm.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.